Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals

. Author manuscript; available in PMC: 2024 May 16.

Published in final edited form as: Clin Infect Dis. 2024 May 15;78(5):1175–1184. doi: 10.1093/cid/ciad696

Figure 4. Proportion of participants experiencing symptom and viral load rebound outcomes (A) and odds of viral load rebound when symptom rebound experienced (B), overall and stratified by nirmatrelvir/ritonavir treatment completion status.